(Q45007278)

English

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 December 2017

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer (English)

1 reference

Europe PubMed Central

8 December 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

A Jimeno

1

1 reference

Europe PubMed Central

8 December 2017

K Shirai

2

1 reference

Europe PubMed Central

8 December 2017

M Choi

3

1 reference

Europe PubMed Central

8 December 2017

J Laskin

4

1 reference

Europe PubMed Central

8 December 2017

M Kochenderfer

5

1 reference

Europe PubMed Central

8 December 2017

A Spira

6

1 reference

Europe PubMed Central

8 December 2017

V Cline-Burkhardt

7

1 reference

Europe PubMed Central

8 December 2017

E Winquist

8

1 reference

Europe PubMed Central

8 December 2017

D Hausman

9

1 reference

Europe PubMed Central

8 December 2017

L Walker

10

1 reference

Europe PubMed Central

8 December 2017

R B Cohen

11

1 reference

Europe PubMed Central

8 December 2017

publication date

18 December 2014

1 reference

Europe PubMed Central

8 December 2017

Annals of Oncology

1 reference

Europe PubMed Central

8 December 2017

26

1 reference

Europe PubMed Central

8 December 2017

3

1 reference

Europe PubMed Central

8 December 2017

556-561

1 reference

Europe PubMed Central

8 December 2017

The PI3K pathway as drug target in human cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Oncogenic PI3K and its role in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

The mutational landscape of head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Comprehensive molecular characterization of human colon and rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

PIK3CA mutations and copy number gains in human lung cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

New phosphatidylinositol 3-kinase inhibitors for cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Targeting the HER-kinase axis in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU574

21 January 2018

Identifiers

10.1093/ANNONC/MDU574

1 reference

Europe PubMed Central

8 December 2017

1 reference

Europe PubMed Central

8 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45007278&oldid=2062268531"